- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06789562
F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer
Comparison of F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- The optimal treatment of non-small cell lung cancer (NSCLC) relies on accurate disease staging that is based on the TNM system which relies on tumor size, regional nodal involvement, and the presence of metastasis.
- CT is the standard modality used to assess the intra-thoracic spread but false negative CT scans have been reported and were related to the presence of metastasis in normal sized lymph nodes and false positive findings have been related to lymph node enlargement due to benign process.
PET is most widely used in thoracic oncology because of its superiority over other imaging techniques in staging nodal and metastatic disease, however, the poor anatomic details of PET can lead to errors in diagnosis and staging.
• To solve this problem, CT is combined with PET to provide matched morphological and functional data. The diagnostic capability of PET/CT in the preoperative staging of lung cancer is superior to that of CT alone and PET alone as it has the advantage of a more accurate assignment of tumor stage (T stage) and defining the lymph node stage (N stage) as well as reduction of the number of useless thoracotomies
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Walaa Gamal, assistant lecturer
- Phone Number: 01065037395
- Email: dr.walaa196@gmail.com
Study Contact Backup
- Name: Nahla Moustafa, assistant professor
- Phone Number: 01009466255
- Email: Nahla_bashank_2006@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with pathologically proven NSCLC who underwent initial PET/CT images.
- All patients ≥ 18 years.
Exclusion Criteria:
- Patients who had started treatment before initial PET/CT. Patients with glucose level < 200 mg/dl. Patients with another malignant condition.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.
Time Frame: Baseline
|
detect added value of F-18FDG PET/CT .
|
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F-18 FDG PET/CTand CT in lung
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.